Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Key Takeaway: Incyte presented results from the pivotal Phase 3 frontMIND trial of Tafasitamab at the 2026 EHA Congress. The trial showed prolonged progression-free survival for patients receiving Tafasitamab in combination therapy. Further details on the trial's outcomes and implications for treatment were discussed during the plenary session.